Platelet-engineered CAR-T cells as adjuvant therapy after cancer surgery
Proceedings of the National Academy of Sciences · 23.12.2025 · 122 (51)
DOI: 10.1073/pnas.2522020122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 18.12.2025. Verfasst von Yixin Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Blood Platelets, Receptors, Chimeric Antigen, Pancreatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIBIB NIH HHS, HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB).
Abstract (Originalsprache)
Surgery remains the mainstay treatment for many kinds of solid tumors, while tumor recurrence frequently occurs. Adjuvant therapy can reduce the risk of recurrence and improve the prognosis of surgery. Chimeric antigen receptor (CAR)-T cell therapy can be leveraged as an alternative adjuvant therapy to clear residual cancer cells and prevent tumor recurrence. However, systemic administration of CAR-T often results in insufficient tumor infiltration and side effects to normal organs. Given that platelets can preferentially accumulate at postsurgical wounds, we proposed that conjugating platelets to CAR-T cells may enhance the accumulation of the CAR-T cells within the surgical bed after the resection of solid tumors. In this study, we conjugated platelets to B7-H3.CAR-T cells via click chemistry. In postsurgical human pancreatic cancer mouse models, platelet-CAR-T cells showed enhanced tumor infiltration and elevated antitumor cytokine levels, resulting in superior suppression effects on tumor recurrence, compared with CAR-T cells. Additionally, platelet-CAR-T cells showed enhanced efficacy in inhibiting metastasis and prolonging the survival time of the mice in postsurgical triple-negative breast cancer (TNBC) models. Mechanistic studies revealed that platelet activation could improve the CAR-T cell activity and persistence, as evidenced by an upregulation of genes associated with T cell infiltration and a downregulation of genes related to T cell exhaustion. Finally, we further validated the biosafety profile and efficacy of platelet-CAR-T in a postsurgical patient-derived xenograft TNBC-bearing humanized mouse model. The results suggested that the CAR-T cell strengthened by platelet engineering is a promising adjuvant therapy against postsurgical tumor recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705.
- Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705.
- Wisconsin Center for NanoBioSystems, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705.
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599.
- Department of Biomedical Engineering, Emory University, Atlanta, GA 30322.
- Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30332.
ORCID-Profile: Huan Yang, Sichen Yuan, Allie Barrett, Bo Liu, Gianpietro Dotti, Quanyin Hu
Förderung
- NCI NIH HHS
- NIBIB NIH HHS
- HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB)
- HHS | NIH | National Cancer Institute (NCI)
Zitieren
APA
Wang, Y., Ogunnaike, E., Yang, H., Yuan, S., Hong, R., Barrett, A., Ebong, E., Liu, B., Dotti, G., & Hu, Q. (2025). Platelet-engineered CAR-T cells as adjuvant therapy after cancer surgery. Proceedings of the National Academy of Sciences, 122(51). https://doi.org/10.1073/pnas.2522020122
Vancouver
Wang Y, Ogunnaike E, Yang H, Yuan S, Hong R, Barrett A, et al. Platelet-engineered CAR-T cells as adjuvant therapy after cancer surgery. Proceedings of the National Academy of Sciences. 2025;122(51). doi:10.1073/pnas.2522020122
BibTeX
@article{Wang2025,
author = {Wang, Yixin and Ogunnaike, Edikan and Yang, Huan and Yuan, Sichen and Hong, Rachel and Barrett, Allie and Ebong, Emem and Liu, Bo and Dotti, Gianpietro and Hu, Quanyin},
title = {Platelet-engineered CAR-T cells as adjuvant therapy after cancer surgery},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {51},
doi = {10.1073/pnas.2522020122}
}
EUVIMED